Niklaus G Schaefer1, Engles James, Richard L Wahl. 1. Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Sciences, Sidney Kimmell Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-0817, USA.
Abstract
PURPOSE: To assess the possible radiosensitizing capabilities of two different poly(ADP-ribose) polymerase (PARP) inhibitors in combination with external beam and I-tositumomab in a non-Hodgkin's lymphoma cell line. METHODS AND MATERIALS: Epstein-Barr virus-infected human Raji lymphoma cells with lentivirally transfected green fluorescent protein and luciferase in log-phase growth were incubated with various doses of AZD-2281 and ABT-888 24 h before external beam radiation exposure. A 500 nmol/l concentration of AZD-2281 and ABT-888 was used to assess the growth curve of Raji lymphoma cells over 5 days. The number of double-stranded breaks was visually assessed using a H2AX antibody and confocal microscopy. Intracellular PARP activity was measured 2 h after incubation with AZD-2281 (500 nmol/l) and ABT-888 using a colorimetric PARP assay kit. The radiosensitizing effect of AZD-2281 (500 nmol/l) with various doses of I-tositumomab was assessed after 24 h. RESULTS: A volume of 500 nmol/l of AZD-2281 and 500 nmol/l of ABT-888, in combination with 0, 4, 8, and 12 Gy external beam radiation, showed a 5.2, 7.1, 10.1, and 33.1% radiosensitization. A measure of 500 nmol/l AZD-2281 and ABT-888 significantly reduced the percentage of viable cells on days 3-5 compared with controls. The maximal relative reduction in viable cells was 78.5%, and this occurred with AZD-2281 (500 nmol/l) on day 5. AZD-2281 revealed a higher number of double-stranded breaks with confocal microscopy than did ABT-888. Two hours after incubation of Raji cells with 500 nmol/l of AZD-2281 or ABT-888, the colorimetric PARP activity assay showed a reduction of 30.36% with ABT-888 and of 47.8% with AZD-2281. Combining AZD-2281 (500 nmol/l) with 0, 5 μCi (0.185 MBq), 10 μCi (0.37 MBq) and 20 μCi (0.74 MBq) ¹³¹I-tositumomab revealed a significant reduction in cell viability after 24 h with 5 μCi (0.185 MBq) (P<0.01) and 10 μCi (0.37 MBq) (P<0.01) radiation dose. CONCLUSION: PARP inhibitors AZD-2281 and ABT-888 are highly radiosensitizing agents when used before external beam radiation and ¹³¹I-tositumomab.
PURPOSE: To assess the possible radiosensitizing capabilities of two different poly(ADP-ribose) polymerase (PARP) inhibitors in combination with external beam and I-tositumomab in a non-Hodgkin's lymphoma cell line. METHODS AND MATERIALS: Epstein-Barr virus-infected human Raji lymphoma cells with lentivirally transfected green fluorescent protein and luciferase in log-phase growth were incubated with various doses of AZD-2281 and ABT-888 24 h before external beam radiation exposure. A 500 nmol/l concentration of AZD-2281 and ABT-888 was used to assess the growth curve of Raji lymphoma cells over 5 days. The number of double-stranded breaks was visually assessed using a H2AX antibody and confocal microscopy. Intracellular PARP activity was measured 2 h after incubation with AZD-2281 (500 nmol/l) and ABT-888 using a colorimetric PARP assay kit. The radiosensitizing effect of AZD-2281 (500 nmol/l) with various doses of I-tositumomab was assessed after 24 h. RESULTS: A volume of 500 nmol/l of AZD-2281 and 500 nmol/l of ABT-888, in combination with 0, 4, 8, and 12 Gy external beam radiation, showed a 5.2, 7.1, 10.1, and 33.1% radiosensitization. A measure of 500 nmol/l AZD-2281 and ABT-888 significantly reduced the percentage of viable cells on days 3-5 compared with controls. The maximal relative reduction in viable cells was 78.5%, and this occurred with AZD-2281 (500 nmol/l) on day 5. AZD-2281 revealed a higher number of double-stranded breaks with confocal microscopy than did ABT-888. Two hours after incubation of Raji cells with 500 nmol/l of AZD-2281 or ABT-888, the colorimetric PARP activity assay showed a reduction of 30.36% with ABT-888 and of 47.8% with AZD-2281. Combining AZD-2281 (500 nmol/l) with 0, 5 μCi (0.185 MBq), 10 μCi (0.37 MBq) and 20 μCi (0.74 MBq) ¹³¹I-tositumomab revealed a significant reduction in cell viability after 24 h with 5 μCi (0.185 MBq) (P<0.01) and 10 μCi (0.37 MBq) (P<0.01) radiation dose. CONCLUSION:PARP inhibitors AZD-2281 and ABT-888 are highly radiosensitizing agents when used before external beam radiation and ¹³¹I-tositumomab.
Authors: Apostolos Menegakis; Ala Yaromina; Wolfgang Eicheler; Annegret Dörfler; Bettina Beuthien-Baumann; Howard D Thames; Michael Baumann; Mechthild Krause Journal: Int J Radiat Biol Date: 2009-11 Impact factor: 2.694
Authors: Thomas E Witzig; Leo I Gordon; Fernando Cabanillas; Myron S Czuczman; Christos Emmanouilides; Robin Joyce; Brad L Pohlman; Nancy L Bartlett; Gregory A Wiseman; Norman Padre; Antonio J Grillo-López; Pratik Multani; Christine A White Journal: J Clin Oncol Date: 2002-05-15 Impact factor: 44.544
Authors: Franck Morschhauser; John Radford; Achiel Van Hoof; Umberto Vitolo; Pierre Soubeyran; Herve Tilly; Peter C Huijgens; Arne Kolstad; Francesco d'Amore; Marcos Gonzalez Diaz; Mario Petrini; Catherine Sebban; Pier Luigi Zinzani; Marinus H J van Oers; Wim van Putten; Angelika Bischof-Delaloye; Ama Rohatiner; Gilles Salles; Jens Kuhlmann; Anton Hagenbeek Journal: J Clin Oncol Date: 2008-10-14 Impact factor: 44.544
Authors: Andres Forero; Paul L Weiden; Julie M Vose; Susan J Knox; Albert F LoBuglio; Jordan Hankins; Michael L Goris; Vincent J Picozzi; Don B Axworthy; Hazel B Breitz; Robert B Sims; Richard G Ghalie; Sui Shen; Ruby F Meredith Journal: Blood Date: 2004-03-02 Impact factor: 22.113
Authors: Khurram Khan; Koji Araki; Daiyou Wang; Guayan Li; Xin Li; Jie Zhang; Weizheng Xu; Randall K Hoover; Susan Lauter; Bert O'Malley; Rena G Lapidus; Daqing Li Journal: Head Neck Date: 2010-03 Impact factor: 3.147
Authors: Shingo Baba; Steve Y Cho; Zhaohui Ye; Linzhao Cheng; James M Engles; Richard L Wahl Journal: Mol Imaging Date: 2007 Sep-Oct Impact factor: 3.250
Authors: C Grana; M Chinol; C Robertson; C Mazzetta; M Bartolomei; C De Cicco; M Fiorenza; M Gatti; P Caliceti; G Paganelli Journal: Br J Cancer Date: 2002-01-21 Impact factor: 7.640
Authors: Kim A Reiss; Joseph M Herman; Deborah Armstrong; Marianna Zahurak; Anthony Fyles; Anthony Brade; Michael Milosevic; Laura A Dawson; Angela Scardina; Patricia Fischer; Amy Hacker-Prietz; Robert J Kinders; Lihua Wang; Alice Chen; Sarah Temkin; Naomi Horiba; Lee-Anne Stayner; Lillian L Siu; Nilofer S Azad Journal: Gynecol Oncol Date: 2017-01-18 Impact factor: 5.482
Authors: Kim A Reiss; Joseph M Herman; Marianna Zahurak; Anthony Brade; Laura A Dawson; Angela Scardina; Caitlin Joffe; Emily Petito; Amy Hacker-Prietz; Robert J Kinders; Lihua Wang; Alice Chen; Sarah Temkin; Naomi Horiba; Lillian L Siu; Nilofer S Azad Journal: Clin Cancer Res Date: 2014-10-29 Impact factor: 12.531